HUE045944T2 - Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására - Google Patents

Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására

Info

Publication number: HUE045944T2
Authority: HU; Hungary
Prior art keywords: molecules; methods; devices; producing heterodimeric; heterodimeric
Prior art date: 2012-04-20

Application number

HUE13720614A

Other languages

English (en)

Inventor

Kruif Cornelis De

Linda Hendriks

Ton Logtenberg

Original Assignee

Merus Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-20

Filing date

2013-04-19

Publication date

2020-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE045944(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-19 Application filed by Merus Nv filed Critical Merus Nv

2020-02-28 Publication of HUE045944T2 publication Critical patent/HUE045944T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

HUE13720614A 2012-04-20 2013-04-19 Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására HUE045944T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261635935P	2012-04-20	2012-04-20

Publications (1)

Publication Number	Publication Date
HUE045944T2 true HUE045944T2 (hu)	2020-02-28

Family

ID=48289584

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE13720615A HUE045945T2 (hu)	2012-04-20	2013-04-19	Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására
HUE13720614A HUE045944T2 (hu)	2012-04-20	2013-04-19	Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE13720615A HUE045945T2 (hu)	2012-04-20	2013-04-19	Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására

Country Status (24)

Country	Link
US (12)	US9248182B2 (hu)
EP (4)	EP2838917B1 (hu)
JP (8)	JP6393255B2 (hu)
KR (9)	KR20250025034A (hu)
CN (5)	CN108586610A (hu)
AU (4)	AU2013249986B2 (hu)
CA (2)	CA2870821C (hu)
CY (2)	CY1122153T1 (hu)
DK (2)	DK2838918T3 (hu)
EA (3)	EA202090591A3 (hu)
ES (2)	ES2743399T3 (hu)
HR (2)	HRP20191409T1 (hu)
HU (2)	HUE045945T2 (hu)
LT (2)	LT2838918T (hu)
MX (6)	MX360109B (hu)
NZ (5)	NZ772318A (hu)
PL (2)	PL2838917T3 (hu)
PT (2)	PT2838918T (hu)
RS (2)	RS59263B1 (hu)
SG (6)	SG10201607369QA (hu)
SI (2)	SI2838918T1 (hu)
SM (2)	SMT201900493T1 (hu)
WO (2)	WO2013157953A1 (hu)
ZA (2)	ZA201407834B (hu)

Families Citing this family (437)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2368733T3 (es) †	2002-07-18	2011-11-21	Merus B.V.	Producción recombinante de mezclas de anticuerpos.
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
EP2395016A3 (en)	2003-05-30	2012-12-19	Merus B.V.	Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
ES2592271T3 (es)	2005-03-31	2016-11-29	Chugai Seiyaku Kabushiki Kaisha	Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
EP4001409A1 (en)	2006-03-31	2022-05-25	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
WO2007114325A1 (ja)	2006-03-31	2007-10-11	Chugai Seiyaku Kabushiki Kaisha	二重特異性抗体を精製するための抗体改変方法
WO2008027986A2 (en)	2006-09-01	2008-03-06	Therapeutic Human Polyclonals, Inc.	Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
KR101485197B1 (ko)	2006-09-07	2015-01-23	크루셀 홀란드 비.브이.	인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
CA2700394C (en)	2007-09-26	2017-10-24	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
JP5787446B2 (ja)	2009-03-19	2015-09-30	中外製薬株式会社	抗体定常領域改変体
JP5717624B2 (ja)	2009-03-19	2015-05-13	中外製薬株式会社	抗体定常領域改変体
MX2011010168A (es)	2009-04-07	2011-10-11	Roche Glycart Ag	Anticuerpos biespecificos, trivalentes.
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
US9493578B2 (en)	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR20120108967A (ko)	2009-09-16	2012-10-05	제넨테크, 인크.	코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
US10150808B2 (en)	2009-09-24	2018-12-11	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant regions
US9796788B2 (en)	2010-02-08	2017-10-24	Regeneron Pharmaceuticals, Inc.	Mice expressing a limited immunoglobulin light chain repertoire
RU2724663C2 (ru)	2010-02-08	2020-06-25	Ридженерон Фармасьютикалз, Инк.	Мышь с общей легкой цепью
US20130045492A1 (en)	2010-02-08	2013-02-21	Regeneron Pharmaceuticals, Inc.	Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
JP5889181B2 (ja)	2010-03-04	2016-03-22	中外製薬株式会社	抗体定常領域改変体
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
CN103052649B (zh)	2010-07-29	2015-12-16	Xencor公司	具有修改的等电点的抗体
TWI452136B (zh)	2010-11-17	2014-09-11	中外製藥股份有限公司	A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
BR112013019975A2 (pt)	2011-02-28	2017-08-01	Hoffmann La Roche	proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CA2824824A1 (en)	2011-02-28	2012-09-07	F. Hoffmann-La Roche Ag	Monovalent antigen binding proteins
JP5977814B2 (ja)	2011-04-08	2016-08-24	アムジエン・インコーポレーテツド	増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
US10130081B2 (en)	2011-08-05	2018-11-20	Regeneron Pharmaceuticals, Inc.	Humanized universal light chain mice
RU2605390C2 (ru)	2011-08-23	2016-12-20	Рош Гликарт Аг	Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
BR112014010257A2 (pt)	2011-10-31	2017-04-18	Chugai Pharmaceutical Co Ltd	molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
CA2862745A1 (en)	2012-01-26	2013-08-01	Amgen Inc.	Growth differentiation factor 15 (gdf-15) polypeptides
PL2838917T3 (pl) *	2012-04-20	2019-12-31	Merus N.V.	Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do Ig
JP6514103B2 (ja)	2012-07-06	2019-05-15	ゲンマブビー．ブイ．	三重変異を有する二量体タンパク質
ES2692951T3 (es)	2012-09-27	2018-12-05	Merus N.V.	Anticuerpos IgG biespecíficos como acopladores de células T
US10087250B2 (en)	2012-10-08	2018-10-02	Roche Glycart Ag	Fc-free antibodies comprising two fab-fragments and methods of use
CA2892623C (en)	2012-11-27	2020-08-11	Ajou University Industry-Academic Cooperation Foundation	Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
CA3211863A1 (en)	2013-01-14	2014-07-17	Xencor, Inc.	Novel heterodimeric proteins
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
EP2945969A1 (en)	2013-01-15	2015-11-25	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
JP6133444B2 (ja)	2013-02-26	2017-05-24	ロシュグリクアートアーゲー	二重特異性ｔ細胞活性化抗原結合分子
CA2896370A1 (en)	2013-02-26	2014-09-04	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
WO2014145907A1 (en)	2013-03-15	2014-09-18	Xencor, Inc.	Targeting t cells with heterodimeric proteins
CN105143262A (zh)	2013-04-29	2015-12-09	豪夫迈·罗氏有限公司	结合人fcrn的修饰的抗体和使用方法
KR20160003803A (ko)	2013-04-29	2016-01-11	에프. 호프만-라 로슈 아게	FcRn 결합이 제거된 항-IGF-1R 항체 및 혈관 눈 질환의 치료에 있어서 이의 용도
CA2904805A1 (en)	2013-04-29	2014-11-06	F. Hoffmann-La Roche Ag	Fc-receptor binding modified asymmetric antibodies and methods of use
AR097181A1 (es) *	2013-07-31	2016-02-24	Amgen Inc	Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)
CA2925256C (en)	2013-09-27	2023-08-15	Chugai Seiyaku Kabushiki Kaisha	Method for producing polypeptide heteromultimer
MX2016003593A (es)	2013-10-11	2016-06-02	Hoffmann La Roche	Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
PL3083680T3 (pl)	2013-12-20	2020-06-29	F. Hoffmann-La Roche Ag	Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
CN111228509A (zh)	2014-01-03	2020-06-05	豪夫迈·罗氏有限公司	双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及其作为血脑屏障穿梭物的应用
CN111057147B (zh)	2014-01-06	2023-11-10	豪夫迈·罗氏有限公司	单价血脑屏障穿梭模块
RU2727639C2 (ru)	2014-01-15	2020-07-22	Ф.Хоффманн-Ля Рош Аг	Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
EP3786186A1 (en)	2014-02-28	2021-03-03	Merus N.V.	Antibodies that bind egfr and erbb3
KR20160145560A (ko)	2014-02-28	2016-12-20	메뤼스 엔.페.	ErbB-2와 ErbB-3에 결합하는 항체
KR102276752B1 (ko)	2014-03-21	2021-07-13	리제너론 파마슈티칼스 인코포레이티드	단일 도메인 결합 단백질을 생산하는 비-인간 동물
HRP20200164T1 (hr)	2014-03-28	2020-05-01	Xencor, Inc.	Bispecifična protutijela koja se vežu na cd38 i cd3
UA117289C2 (uk)	2014-04-02	2018-07-10	Ф. Хоффманн-Ля Рош Аг	Мультиспецифічне антитіло
SG11201608054YA (en)	2014-04-02	2016-10-28	Hoffmann La Roche	Method for detecting multispecific antibody light chain mispairing
KR20170026362A (ko)	2014-06-26	2017-03-08	에프. 호프만-라 로슈 아게	항-ｂｒｄｕ 항체 및 사용 방법
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EA038958B1 (ru)	2014-08-04	2021-11-15	Ф. Хоффманн-Ля Рош Аг	Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
EP2982692A1 (en)	2014-08-04	2016-02-10	EngMab AG	Bispecific antibodies against CD3epsilon and BCMA
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
WO2016055592A1 (en)	2014-10-09	2016-04-14	Engmab Ag	Bispecific antibodies against cd3epsilon and ror1
JP6576456B2 (ja)	2014-11-06	2019-09-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種
MX378451B (es)	2014-11-06	2025-03-11	Hoffmann La Roche	Variantes de regiòn fc con uniòn del receptor fc neonatal (fcrn) modificado y mètodos de uso.
DK3221356T3 (da)	2014-11-20	2020-11-02	Hoffmann La Roche	T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
FI4141032T3 (fi)	2014-11-20	2024-07-31	Hoffmann La Roche	T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
EP3023437A1 (en)	2014-11-20	2016-05-25	EngMab AG	Bispecific antibodies against CD3epsilon and BCMA
CA2968162A1 (en)	2014-11-20	2016-05-26	F. Hoffmann-La Roche Ag	Common light chains and methods of use
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
PE20171103A1 (es)	2014-11-26	2017-08-07	Xencor Inc	Anticuerpos heterodimericos que se unen a cd3 y cd38
DK3223845T3 (da)	2014-11-26	2021-08-16	Xencor Inc	Heterodimere antistoffer, der binder cd3 og cd20
JP6721590B2 (ja)	2014-12-03	2020-07-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性抗体
EP3237449A2 (en)	2014-12-22	2017-11-01	Xencor, Inc.	Trispecific antibodies
CN105820251B (zh) *	2015-01-08	2019-10-15	江苏康宁杰瑞生物制药有限公司	具有共同轻链的双特异性抗体或抗体混合物
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
CA2979702A1 (en)	2015-03-19	2016-09-22	Regeneron Pharmaceuticals, Inc.	Non-human animals that select for light chain variable regions that bind antigen
WO2016154601A1 (en)	2015-03-26	2016-09-29	Acceleron Pharma Inc.	Follistatin-related fusion proteins and uses thereof
WO2016159213A1 (ja)	2015-04-01	2016-10-06	中外製薬株式会社	ポリペプチド異種多量体の製造方法
PL3313877T3 (pl)	2015-06-24	2020-11-02	F. Hoffmann-La Roche Ag	Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
JP7010811B2 (ja)	2015-07-10	2022-02-10	メルスナムローゼフェンノートシャップ	ヒトｃｄ３結合抗体
ME03772B (me)	2015-07-10	2021-04-20	Genmab As	Konjugati antitijela specifičnog za axl i lijeka za liječenje kancera
JP2018526981A (ja)	2015-07-15	2018-09-20	ゲンマブエー／エス	ヒト化またはキメラｃｄ３抗体
AU2016312259B2 (en) *	2015-08-26	2018-12-06	Bison Therapeutics Inc.	Multispecific antibody platform and related methods
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP6937746B2 (ja)	2015-10-02	2021-09-22	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗ｃｄ１９×ｃｄ３ｔ細胞活性化抗原結合分子
EP3150637A1 (en)	2015-10-02	2017-04-05	F. Hoffmann-La Roche AG	Multispecific antibodies
WO2017055395A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055385A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
RU2729371C1 (ru)	2015-10-02	2020-08-06	Ф. Хоффманн-Ля Рош Аг	Биспецифические антитела, специфические к pd1 и tim3
HK1254967A1 (zh)	2015-10-02	2019-08-02	豪夫迈‧罗氏有限公司	結合間皮素和cd3的雙特異性t細胞活化性抗原結合分子
WO2017055388A2 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific t cell activating antigen binding molecules
BR112018000835A2 (pt)	2015-10-02	2018-09-11	Hoffmann La Roche	molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
WO2017055393A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
JP6734919B2 (ja)	2015-10-02	2020-08-05	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
KR101851380B1 (ko)	2015-10-12	2018-04-23	아주대학교산학협력단	효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
KR20180100305A (ko)	2015-10-23	2018-09-10	메뤼스 엔.페.	암 성장을 억제하는 결합 분자
JP6949016B2 (ja)	2015-10-29	2021-10-13	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗バリアントＦｃ領域抗体および使用法
CN113862300A (zh) *	2015-10-29	2021-12-31	豪夫迈·罗氏有限公司	具有共同轻链的转基因兔
KR20180098567A (ko)	2015-12-01	2018-09-04	젠맵 비. 브이	항-dr5 항체 및 그의 사용 방법
WO2017100372A1 (en)	2015-12-07	2017-06-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and psma
EP3178848A1 (en)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
PL3387015T3 (pl)	2015-12-09	2022-02-14	F. Hoffmann-La Roche Ag	Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
CN106883297B (zh) *	2015-12-16	2019-12-13	苏州康宁杰瑞生物科技有限公司	基于ch3结构域的异二聚体分子、其制备方法及用途
CN108368166B (zh)	2015-12-28	2023-03-28	中外制药株式会社	提高含fc区多肽纯化效率的方法
ES2837428T3 (es)	2016-01-08	2021-06-30	Hoffmann La Roche	Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
CN109069640B (zh)	2016-03-14	2023-10-03	中外制药株式会社	用于癌症治疗的诱导细胞损伤的治疗药物
US11291721B2 (en)	2016-03-21	2022-04-05	Marengo Therapeutics, Inc.	Multispecific and multifunctional molecules and uses thereof
HRP20230528T1 (hr)	2016-03-22	2023-08-04	F. Hoffmann - La Roche Ag	Bispecifične molekule t stanica aktivirane proteazom
WO2017186853A1 (en) *	2016-04-27	2017-11-02	Bcrt Holding Bv	T cell-based bi-specific immunotherapeutics
SG11201809620UA (en)	2016-05-02	2018-11-29	Hoffmann La Roche	The contorsbody - a single chain target binder
CN109475627B (zh) *	2016-05-26	2023-01-06	齐鲁普吉湾生物治疗公司	抗体混合物
EP3252078A1 (en)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2017218707A2 (en)	2016-06-14	2017-12-21	Xencor, Inc.	Bispecific checkpoint inhibitor antibodies
EP3475304B1 (en)	2016-06-28	2022-03-23	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
JP6983824B2 (ja)	2016-07-04	2021-12-17	エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft	新規抗体フォーマット
KR20240017129A (ko)	2016-07-14	2024-02-06	젠맵 에이/에스	Cd40 및 cd137에 대한 다중특이적 항체
AU2017310163B2 (en)	2016-08-10	2021-09-09	Ajou University Industry-Academic Cooperation Foundation	Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP4342912A3 (en)	2016-09-23	2024-05-22	Merus N.V.	Binding molecules that modulate a biological activity expressed by a cell
MY194994A (en) *	2016-09-29	2022-12-30	Beijing Hanmi Pharmaceutical Co Ltd	Heterodimeric immunoglobulin constructs and preparation methods thereof
US10882918B2 (en)	2016-09-30	2021-01-05	Hoffmann-La Roche Inc.	Bispecific T cell activating antigen binding molecules
JP6785372B2 (ja)	2016-09-30	2020-11-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
CA3040504A1 (en)	2016-10-14	2018-04-19	Xencor, Inc.	Il15/il15ra heterodimeric fc-fusion proteins
KR102617264B1 (ko) *	2016-10-19	2023-12-29	인벤라 인코포레이티드	항체 구조물
CA3041988A1 (en)	2016-11-01	2018-05-11	Genmab B.V.	Polypeptide variants and uses thereof
PE20191080A1 (es)	2016-11-18	2019-08-20	Beijing Hanmi Pharmaceutical Co Ltd	Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
US11111305B2 (en)	2017-01-09	2021-09-07	Torch Therapeutics	Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
DK3579848T3 (da)	2017-02-08	2025-01-20	Dragonfly Therapeutics Inc	Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
JP7577446B2 (ja)	2017-02-10	2024-11-05	ジェンマブビー．ブイ．	ポリペプチドバリアントおよびそれらの使用
US20200291089A1 (en)	2017-02-16	2020-09-17	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
KR20240060739A (ko)	2017-02-20	2024-05-08	드래곤플라이 쎄라퓨틱스, 인크.	Her2, nkg2d 및 cd16에 결합하는 단백질
JP7556687B2 (ja) *	2017-02-24	2024-09-26	中外製薬株式会社	薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
US20200239579A1 (en)	2017-03-09	2020-07-30	Genmab A/S	Antibodies against pd-l1
RU2750721C2 (ru)	2017-03-10	2021-07-01	Ф. Хоффманн-Ля Рош Аг	Способ получения мультиспецифических антител
AU2018242227B2 (en)	2017-03-31	2025-04-10	Genmab Holding B.V.	Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof
CA3058342A1 (en)	2017-03-31	2018-10-04	Merus N.V.	Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
CN110997000A (zh)	2017-03-31	2020-04-10	美勒斯公司	用于治疗ErbB-2/ErbB-3阳性肿瘤的抗体
US11780925B2 (en)	2017-03-31	2023-10-10	Merus N.V.	ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
WO2018177324A1 (zh) *	2017-04-01	2018-10-04	北京韩美药品有限公司	抗pd‐l1/抗pd‐1天然抗体结构样异源二聚体形式双特异抗体及其制备
CN110382525B (zh)	2017-04-03	2023-10-20	豪夫迈·罗氏有限公司	免疫缀合物
AU2018247767B2 (en)	2017-04-03	2025-01-30	F. Hoffmann-La Roche Ag	Antibodies binding to STEAP-1
EP3606946B1 (en)	2017-04-03	2022-08-24	F. Hoffmann-La Roche AG	Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
EP4516809A2 (en)	2017-04-05	2025-03-05	F. Hoffmann-La Roche AG	Bispecific antibodies specifically binding to pd1 and lag3
JOP20190222A1 (ar)	2017-04-11	2019-09-24	Zymeworks Inc	الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
EP3609537A1 (en)	2017-04-13	2020-02-19	H. Hoffnabb-La Roche Ag	An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
US12195551B2 (en)	2017-05-17	2025-01-14	Merus N.V.	Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
WO2018222901A1 (en)	2017-05-31	2018-12-06	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
KR20200014304A (ko)	2017-06-02	2020-02-10	에프. 호프만-라 로슈 아게	암의 치료를 위한 제ii형 항-cd20 항체 및 항-cd20/항-cd3 이중특이적 항체
MA49259A (fr)	2017-06-07	2020-04-15	Genmab Bv	Anticorps thérapeutiques à base d'hexamères d'igg mutées
US11845806B2 (en)	2017-06-14	2023-12-19	Dingfu Biotarget Co., Ltd.	Proteinaceous heterodimer and use thereof
GB201709970D0 (en)	2017-06-22	2017-08-09	Kymab Ltd	Bispecific antigen-binding molecules
CA3067603A1 (en)	2017-06-30	2019-01-03	Xencor, Inc.	Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
SG11202000014UA (en) *	2017-07-06	2020-01-30	Merus Nv	Binding molecules that modulate a biological activity expressed by a cell
EP3649155A1 (en)	2017-07-06	2020-05-13	Merus N.V.	Bispecific anti pd1-anti tim3 antibodies
EP3649156A1 (en)	2017-07-06	2020-05-13	Merus N.V.	Antibodies that modulate a biological activity expressed by a cell
AR112603A1 (es)	2017-07-10	2019-11-20	Lilly Co Eli	Anticuerpos biespecíficos inhibidores de punto de control
WO2019014912A1 (zh) *	2017-07-21	2019-01-24	赵磊	一种异二聚体蛋白及其制备方法
WO2019025545A1 (en)	2017-08-04	2019-02-07	Genmab A/S	BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
JP2020530028A (ja)	2017-08-09	2020-10-15	メルスナムローゼフェンノートシャップ	ＥＧＦＲ及びｃＭＥＴに結合する抗体
WO2019070047A1 (ja)	2017-10-06	2019-04-11	小野薬品工業株式会社	二重特異性抗体
AU2018353420A1 (en)	2017-10-20	2020-04-16	F. Hoffmann-La Roche Ag	Method for generating multispecific antibodies from monospecific antibodies
CN111372947A (zh)	2017-10-30	2020-07-03	豪夫迈·罗氏有限公司	在体内从单特异性抗体产生多特异性抗体的方法
IL272747B2 (en)	2017-11-01	2025-04-01	Hoffmann La Roche	Bispecific antibodies 1 + 2
CA3079129C (en)	2017-11-01	2023-02-28	F. Hoffmann-La Roche Ag	Trifab-contorsbody
JP2021500902A (ja)	2017-11-01	2021-01-14	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
CN111295392A (zh)	2017-11-01	2020-06-16	豪夫迈·罗氏有限公司	Compbody–多价靶结合物
CN112272563A (zh)	2017-11-08	2021-01-26	Xencor股份有限公司	使用新颖抗pd-1序列的双特异性和单特异性抗体
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021504413A (ja)	2017-12-01	2021-02-15	メルスナムローゼフェンノートシャップ	組み合わせ治療のための二重特異性抗体及びｉｌ−１５の使用
AU2018378529A1 (en)	2017-12-04	2020-06-18	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-PD-L1/anti-CD47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
MX2020006322A (es)	2017-12-19	2020-09-18	Xencor Inc	Proteinas de fusion il-2 fc modificadas.
KR102575787B1 (ko)	2017-12-21	2023-09-08	에프. 호프만-라 로슈 아게	Hla-a2/wt1에 결합하는 항체
WO2019122054A1 (en)	2017-12-22	2019-06-27	F. Hoffmann-La Roche Ag	Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
EP3737692A4 (en)	2018-01-09	2021-09-29	Elstar Therapeutics, Inc.	CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US20210107988A1 (en)	2018-01-24	2021-04-15	Genmab B.V.	Polypeptide variants and uses thereof
WO2019148410A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1 antibodies
WO2019148412A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1/lag3 bispecific antibodies
CN119733046A (zh)	2018-02-06	2025-04-01	豪夫迈·罗氏有限公司	眼科疾病的治疗
CA3090244A1 (en)	2018-02-08	2019-08-15	Dragonfly Therapeutics, Inc.	Antibody variable domains targeting the nkg2d receptor
WO2019153200A1 (zh)	2018-02-08	2019-08-15	北京韩美药品有限公司	抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
AU2019218959A1 (en)	2018-02-08	2020-09-03	Genentech, Inc.	Bispecific antigen-binding molecules and methods of use
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
TWI804572B (zh)	2018-02-09	2023-06-11	日商小野藥品工業股份有限公司	雙特異性抗體
KR20200120927A (ko) *	2018-02-11	2020-10-22	베이징 한미 파마슈티컬 컴퍼니 리미티드	항-pd-1/항-vegf 천연 항체 구조-유사 이형이량체형 이중특이성 항체 및 그의 제조
WO2019164930A1 (en)	2018-02-20	2019-08-29	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en)	2018-03-14	2021-01-14	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
KR20200139189A (ko) *	2018-03-30	2020-12-11	메뤼스 엔.페.	다가 항체
US10982006B2 (en)	2018-04-04	2021-04-20	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
CN111954537A (zh)	2018-04-09	2020-11-17	美国安进公司	生长分化因子15融合蛋白
US20210163594A1 (en) *	2018-04-17	2021-06-03	Invenra Inc.	Binding molecules
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es)	2018-04-18	2020-11-25	Hoffmann La Roche	Anticuerpos multiespecíficos y utilización de los mismos
SG11202010163QA (en)	2018-04-18	2020-11-27	Xencor Inc	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204655A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
MX2020011552A (es)	2018-05-03	2020-11-24	Genmab Bv	Combinaciones de variantes de anticuerpos y usos de las mismas.
CN113164588A (zh)	2018-05-16	2021-07-23	詹森生物科技公司	治疗癌症并增强t细胞重定向治疗剂的功效的方法
CA3101019A1 (en)	2018-06-01	2019-12-05	Compugen Ltd	Anti-pvrig/anti-tigit bispecific antibodies and methods of use
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
US12275797B2 (en)	2018-06-22	2025-04-15	Genmab Holding B.V.	Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
EP3818083A2 (en)	2018-07-03	2021-05-12	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
MX2020013631A (es)	2018-07-13	2021-03-25	Genmab As	Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas.
EP3820890A1 (en)	2018-07-13	2021-05-19	Genmab A/S	Trogocytosis-mediated therapy using cd38 antibodies
EA202091888A1 (ru)	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	Вариабельные домены антител, нацеленные на рецептор nkg2d
GB2576914A (en)	2018-09-06	2020-03-11	Kymab Ltd	Antigen-binding molecules comprising unpaired variable domains produced in mammals
CA3113409A1 (en)	2018-09-19	2020-03-26	Lava Therapeutics B.V.	Dual acting cd1d immunoglobulin
CN113195523A (zh)	2018-10-03	2021-07-30	Xencor股份有限公司	IL-12异源二聚体Fc融合蛋白
AU2019354105A1 (en)	2018-10-04	2021-04-29	Genmab Holding B.V.	Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
MX2021004711A (es)	2018-10-23	2021-07-02	Dragonfly Therapeutics Inc	Proteinas heterodimericas fusionadas con fragmento cristalizable (fc).
CN119033685A (zh)	2018-10-29	2024-11-29	豪夫迈·罗氏有限公司	抗体制剂
AU2019375014A1 (en)	2018-11-06	2021-05-27	BioNTech SE	Antibody formulation
JP2022513708A (ja)	2018-12-05	2022-02-09	モルフォシス・アーゲー	多重特異性抗原結合分子
GB201820687D0 (en)	2018-12-19	2019-01-30	Kymab Ltd	Antagonists
EP3898685A1 (en)	2018-12-20	2021-10-27	Merus N.V.	Clec12axcd3 bispecific antibodies and methods for the treatment of disease
WO2020128049A1 (en)	2018-12-21	2020-06-25	Kymab Limited	Fixaxfx bispecific antibody with common light chain
AU2019410075B2 (en)	2018-12-21	2022-08-25	F. Hoffmann-La Roche Ag	Antibodies binding to CD3
CN113412123A (zh)	2018-12-28	2021-09-17	豪夫迈·罗氏有限公司	用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
CN113439089A (zh)	2018-12-31	2021-09-24	美勒斯公司	截短的多价多元体
EP3906255A1 (en)	2018-12-31	2021-11-10	Merus N.V.	Mixed binding domains
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
SG11202108141VA (en)	2019-02-01	2021-08-30	Lava Therapeutics B V	Novel cd40-binding antibodies
NL2022494B1 (en)	2019-02-01	2020-08-19	Lava Therapeutics B V	Novel CD40-binding antibodies
EP3924384A1 (en)	2019-02-14	2021-12-22	Merus N.V.	Combinations of binding moieties that bind egfr, her2 and her3
CN114409798A (zh) *	2019-02-14	2022-04-29	美勒斯公司	制备包含两种或更多种抗体的组合物
MA54943A (fr) *	2019-02-14	2021-12-22	Merus Nv	Production de compositions comprenant deux anticorps ou plus
CN114026122B (zh)	2019-02-21	2024-12-31	马伦戈治疗公司	结合t细胞相关癌细胞的多功能分子及其用途
JP7579795B2 (ja)	2019-02-21	2024-11-08	マレンゴ・セラピューティクス，インコーポレーテッド	ＮＫｐ３０に結合する抗体分子およびその使用
WO2020172598A1 (en)	2019-02-21	2020-08-27	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
WO2020172601A1 (en)	2019-02-21	2020-08-27	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
CN114126714A (zh)	2019-02-21	2022-03-01	马伦戈治疗公司	抗tcr抗体分子及其用途
CN120230213A (zh)	2019-03-01	2025-07-01	Xencor股份有限公司	结合enpp3和cd3的异二聚抗体
WO2020198683A1 (en) *	2019-03-28	2020-10-01	Ab Studio Inc.	Heteromultimeric proteins and methods of use thereof
WO2020200941A1 (en)	2019-03-29	2020-10-08	F. Hoffmann-La Roche Ag	Spr-based binding assay for the functional analysis of multivalent molecules
TW202039578A (zh)	2019-03-29	2020-11-01	荷蘭商美勒斯公司	Cd3結合分子
CN113677701B (zh)	2019-03-29	2025-02-07	豪夫迈·罗氏有限公司	产生亲合结合多特异性抗体的方法
BR112021020859A2 (pt)	2019-04-25	2022-01-04	Hoffmann La Roche	Conjuntos de polipeptídeos, método para gerar um polipeptídeo, polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico e segundo polipeptídeo precursor heterodimérico
BR112021020843A2 (pt) *	2019-04-25	2022-02-01	Hoffmann La Roche	Conjunto de polipeptídeos precursores heterodiméricos, polipeptídeos heterodiméricos, métodos para gerar um polipeptídeo heterodimérico e para identificar um polipeptídeo heterodimérico multiespecífico, polipeptídeo heterodimérico multiespecífico, primeiro e segundo polipeptídeo precursor heterodimérico
TW202106713A (zh)	2019-04-25	2021-02-16	瑞士商赫孚孟拉羅股份公司	具延長半衰期之可活化治療性多特異性多肽
PH12021552833A1 (en) *	2019-05-09	2023-01-16	Merus Nv	Variant domains for multimerizing proteins and separation thereof
WO2020225456A1 (en)	2019-05-09	2020-11-12	Genmab B.V.	Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
JP7273195B2 (ja)	2019-05-13	2023-05-12	エフ．ホフマン－ラロシュアーゲー	干渉抑制薬物動態イムノアッセイ
JP7317353B2 (ja) *	2019-06-18	2023-07-31	株式会社プロテイン・エクスプレス	ブレビバチルス菌によるヘテロ二量体タンパク質の生産
MX2021015536A (es)	2019-06-19	2022-02-10	Hoffmann La Roche	Metodo para la generacion de una celula que expresa proteina mediante integracion dirigida usando acido ribonucleico mensajero (arnm) de cre.
BR112021026286A2 (pt)	2019-06-26	2022-03-03	Hoffmann La Roche	Método para aumentar o título de polipeptídeo heterólogo e/ou reduzir a produção de lactato de uma célula de mamífero recombinante e métodos para produzir um polipeptídeo heterólogo e uma célula de mamífero recombinante
TW202115115A (zh)	2019-07-02	2021-04-16	瑞士商赫孚孟拉羅股份公司	免疫結合物
KR20220030956A (ko)	2019-07-05	2022-03-11	오노 야꾸힝 고교 가부시키가이샤	Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
JP2022541332A (ja)	2019-07-26	2022-09-22	ヤンセンバイオテツク，インコーポレーテツド	カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
CA3149309A1 (en)	2019-07-30	2021-02-04	Ono Pharmaceutical Co., Ltd.	Bispecific antibody
JP2022543551A (ja)	2019-07-31	2022-10-13	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｇｐｒｃ５ｄに結合する抗体
MX2022001156A (es)	2019-07-31	2022-02-22	Hoffmann La Roche	Anticuerpos que se fijan a gprc5d.
JPWO2021025140A1 (hu)	2019-08-08	2021-02-11
CR20220054A (es)	2019-08-15	2022-06-06	Janssen Biotech Inc	Materiales y métodos para fragmentos variables de cadena única mejorado
MX2022002096A (es)	2019-08-19	2022-03-17	Merus Nv	Tratamiento del cancer con una combinacion de un anticuerpo que se une al receptor 5 acoplado a la proteina g que contiene repeticiones ricas en leucina (lgr5) y al receptor del factor de crecimiento epidermico (egfr) y un inhibidor de topoisomerasa i.
EP3792283A1 (en)	2019-09-16	2021-03-17	Lava Therapeutics B.V.	Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
CN114761436A (zh)	2019-10-24	2022-07-15	美勒斯公司	用于治疗患有her2和her3阳性癌症的受试者的手段及方法
US20220409730A1 (en)	2019-11-01	2022-12-29	InnoCore Technologies Holding B.V.	Dosage form for extended release of an antibody or large protein
JP2023500701A (ja)	2019-11-06	2023-01-10	ジェンマブビー．ブイ．	抗体変種の組み合わせおよびその使用
JP2023504172A (ja)	2019-12-02	2023-02-01	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	ペプチド－ｍｈｃｉｉタンパク質構築物およびそれらの使用
BR112022011854A2 (pt)	2019-12-18	2022-09-06	Hoffmann La Roche	Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
BR112022012010A2 (pt)	2019-12-18	2022-08-30	Hoffmann La Roche	Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
CN114930170A (zh)	2020-01-02	2022-08-19	豪夫迈·罗氏有限公司	用于测定脑中的治疗性抗体量的方法
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
KR20220130724A (ko)	2020-01-16	2022-09-27	젠맵 에이/에스	Cd38 항체의 제제 및 그의 용도
CN114945596A (zh)	2020-01-29	2022-08-26	美勒斯公司	用于调节免疫细胞衔接效应的手段和方法
EP4096707A1 (en)	2020-01-30	2022-12-07	Umoja Biopharma, Inc.	Bispecific transduction enhancer
WO2021155916A1 (en)	2020-02-04	2021-08-12	BioNTech SE	Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
BR112022018176A2 (pt)	2020-03-13	2022-12-06	Janssen Biotech Inc	Materiais e métodos para ligação de siglec-3/cd33
EP4121456A1 (en)	2020-03-18	2023-01-25	Genmab A/S	Antibodies binding to b7h4
WO2021190980A1 (en)	2020-03-22	2021-09-30	Quadrucept Bio Limited	Multimers for viral strain evolution
US20230203466A1 (en) *	2020-04-03	2023-06-29	Medgenome Inc.	Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
BR112022020629A2 (pt)	2020-04-15	2022-11-29	Hoffmann La Roche	Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
WO2021217085A1 (en)	2020-04-24	2021-10-28	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP2023523006A (ja)	2020-04-24	2023-06-01	メルスナムローゼフェンノートシャップ	Ｌｇｒ５及びｅｇｆｒに結合する抗体によるがんの治療
KR20230007384A (ko)	2020-04-30	2023-01-12	브리스톨-마이어스 스큅 컴퍼니	치료 방법
US12157771B2 (en)	2020-05-06	2024-12-03	Dragonfly Therapeutics, Inc.	Proteins binding NKG2D, CD16 and CLEC12A
BR112022022614A2 (pt)	2020-05-11	2023-02-07	Hoffmann La Roche	Métodos para estimular uma resposta imune, melhorar uma imunoterapia, tratar uma doença, reduzir crescimento tumoral, produzir um imunoconjugado e produzir uma composição, método de vacinação, imunoconjugados, composição, usos e kits
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2021235936A1 (en) *	2020-05-21	2021-11-25	Merus N.V.	Methods and means for the production of ig-like molecules
CA3184189A1 (en)	2020-05-27	2021-12-02	Janssen Biotech, Inc.	Proteins comprising cd3 antigen binding domains and uses thereof
KR20230025783A (ko)	2020-06-19	2023-02-23	에프. 호프만-라 로슈 아게	면역 활성화 Fc 도메인 결합 분자
WO2021255146A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cea
US11780920B2 (en)	2020-06-19	2023-10-10	Hoffmann-La Roche Inc.	Antibodies binding to CD3 and CD19
WO2021255143A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and folr1
PE20230835A1 (es)	2020-06-19	2023-05-19	Hoffmann La Roche	Anticuerpos que se unen a cd3
WO2022009052A2 (en)	2020-07-06	2022-01-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
JP2023532807A (ja)	2020-07-08	2023-07-31	ラヴァ・セラピューティクス・エヌ・ヴイ	Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
WO2022018294A1 (en)	2020-07-23	2022-01-27	Genmab B.V.	A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
AR123083A1 (es)	2020-07-29	2022-10-26	Janssen Biotech Inc	Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
WO2022023559A1 (en)	2020-07-31	2022-02-03	Curevac Ag	Nucleic acid encoded antibody mixtures
US20230287088A1 (en)	2020-08-06	2023-09-14	BioNTech SE	Binding agents for coronavirus s protein
MX2023001962A (es)	2020-08-19	2023-04-26	Xencor Inc	Composiciones anti-cd28.
WO2022046922A2 (en)	2020-08-26	2022-03-03	Marengo Therapeutics, Inc.	Antibody molecules that bind to nkp30 and uses thereof
CN116249718A (zh)	2020-08-26	2023-06-09	马伦戈治疗公司	结合至钙网蛋白的多功能性分子及其用途
GB2616354A (en)	2020-08-26	2023-09-06	Marengo Therapeutics Inc	Methods of detecting TRBC1 or TRBC2
WO2022053653A1 (en)	2020-09-10	2022-03-17	Genmab A/S	Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
CA3192251A1 (en)	2020-09-10	2022-03-17	Genmab A/S	Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
MX2023003328A (es)	2020-09-24	2023-03-27	Hoffmann La Roche	Lineas de celulas de mamifero con desactivacion genica.
WO2022069724A1 (en)	2020-10-02	2022-04-07	Genmab A/S	Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
TW202231292A (zh)	2020-10-13	2022-08-16	美商健生生物科技公司	用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
IL302277A (en)	2020-10-22	2023-06-01	Janssen Biotech Inc	Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
CN117487015A (zh)	2020-11-04	2024-02-02	美勒斯公司	用于治疗患有erbb3突变阳性癌症的受试者的手段和方法
CN117120477A (zh)	2020-11-10	2023-11-24	上海齐鲁制药研究中心有限公司	针对密蛋白18a2和cd3的双特异性抗体及其应用
IL303045A (en)	2020-12-10	2023-07-01	Lava Therapeutics N V	Antibodies that bind gamma-delta t cell receptors
MX2023006983A (es)	2020-12-15	2023-06-26	Merus Nv	Tratamiento de canceres con un anticuerpo que se une al receptor 5 acoplado a proteina g (lgr5) y al receptor del factor de crecimiento epidermico (egfr).
CA3204702A1 (en)	2020-12-17	2022-06-23	F. Hoffmann-La Roche Ag	Anti-hla-g antibodies and use thereof
CN116601175A (zh)	2020-12-18	2023-08-15	豪夫迈·罗氏有限公司	用于靶向疗法的前体蛋白和试剂盒
US20240058444A1 (en)	2020-12-18	2024-02-22	Merus N.V.	Antibody composition
JP2024501662A (ja)	2020-12-22	2024-01-15	エフ．ホフマン－ラロシュアーゲー	Ｘｂｐ１を標的とするオリゴヌクレオチド
AU2022206061A1 (en)	2021-01-06	2023-07-06	F. Hoffmann-La Roche Ag	Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022148853A1 (en)	2021-01-11	2022-07-14	F. Hoffmann-La Roche Ag	Immunoconjugates
JP2024512240A (ja)	2021-02-18	2024-03-19	エフ．ホフマン－ラロシュアーゲー	複雑な多段階の抗体相互作用を解明するための方法
BR112023017099A2 (pt)	2021-02-26	2023-11-21	Lava Therapeutics N V	Anticorpos que se ligam a cd123 e a receptores de células t gama-delta
WO2022184659A1 (en)	2021-03-01	2022-09-09	Quadrucept Bio Limited	Antibody domains & multimers
EP4305067A1 (en)	2021-03-09	2024-01-17	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
US12180278B2 (en)	2021-03-24	2024-12-31	Janssen Biotech, Inc.	Antibody targeting CD22 and CD79B
MX2023011266A (es)	2021-03-24	2023-12-07	Janssen Biotech Inc	Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas.
EP4317175A1 (en)	2021-03-31	2024-02-07	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Truncated taci polypeptide and fusion protein and use thereof
MX2023011362A (es)	2021-03-31	2023-10-05	Merus Nv	Anticuerpos multiespecificos novedosos.
WO2022216993A2 (en)	2021-04-08	2022-10-13	Marengo Therapeutics, Inc.	Multifuntional molecules binding to tcr and uses thereof
EP4330282A1 (en)	2021-04-30	2024-03-06	F. Hoffmann-La Roche AG	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4329800A1 (en)	2021-04-30	2024-03-06	F. Hoffmann-La Roche AG	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
JP2024519212A (ja)	2021-05-07	2024-05-09	ジェンマブエー／エス	Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物
US20240239898A1 (en) *	2021-05-10	2024-07-18	Medimmune, Llc	Modified fcrn binding fragments with improved half-life
US20240254245A1 (en)	2021-05-12	2024-08-01	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
US20240392020A1 (en)	2021-05-14	2024-11-28	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Antigen-binding molecule
AU2022295067A1 (en)	2021-06-18	2023-12-21	F. Hoffmann-La Roche Ag	Bispecific anti-ccl2 antibodies
CA3223375A1 (en)	2021-06-21	2022-12-29	Ugur Sahin	Combination dosage regime of cd137 and pd-l1 binding agents
TW202309078A (zh)	2021-07-02	2023-03-01	美商建南德克公司	治療癌症之方法及組成物
KR20240032959A (ko)	2021-07-14	2024-03-12	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	Hgfr 및 egfr에 특이적으로 결합하는 항원-결합 분자, 및 이의 약학적 용도
EP4373859A1 (en)	2021-07-22	2024-05-29	F. Hoffmann-La Roche AG	Heterodimeric fc domain antibodies
JP2024527977A (ja)	2021-07-27	2024-07-26	ノヴァブ，インコーポレイテッド	免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
US20250101103A1 (en)	2021-07-27	2025-03-27	Morphosys Ag	Combinations of antigen binding molecules
CA3224180A1 (en)	2021-07-28	2023-02-02	F. Hoffmann-La Roche Ag	Methods and compositions for treating cancer
KR102351147B1 (ko) *	2021-08-02	2022-01-14	주식회사 바이오뱅크힐링	블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
AU2022338208A1 (en)	2021-09-06	2024-03-21	Genmab A/S	Antibodies capable of binding to cd27, variants thereof and uses thereof
CA3229822A1 (en)	2021-09-13	2023-03-16	Patrick John DOONAN	Cd33 x v?2 multispecific antibodies for the treatment of cancer
WO2023049732A1 (en) *	2021-09-21	2023-03-30	Qilu Puget Sound Biotherapeutics Corporation	HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES
KR20240067092A (ko)	2021-09-23	2024-05-16	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	항-klb 항체 및 용도
EP4405392A1 (en)	2021-09-24	2024-07-31	Janssen Biotech, Inc.	Proteins comprising cd20 binding domains, and uses thereof
TW202323304A (zh)	2021-09-30	2023-06-16	大陸商江蘇恆瑞醫藥股份有限公司	抗ｉｌ２３抗體融合蛋白及用途
CN118055949A (zh)	2021-10-06	2024-05-17	美勒斯公司	使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症
JP7503215B2 (ja)	2021-10-08	2024-06-19	ジェンマブエー／エス	Ｃｄ３０及びｃｄ３に結合する抗体
CN118139648A (zh)	2021-10-14	2024-06-04	豪夫迈·罗氏有限公司	用于治疗癌症的替代的PD1-IL7v免疫缀合物
CA3234731A1 (en)	2021-10-14	2023-04-20	F. Hoffmann-La Roche Ag	New interleukin-7 immunoconjugates
EP4419109A1 (en)	2021-10-21	2024-08-28	LAVA Therapeutics N.V.	Uses of gamma delta t cell activating antibodies
MX2024005392A (es)	2021-11-03	2024-08-06	Janssen Biotech Inc	Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
AU2022389596A1 (en)	2021-11-19	2024-05-30	Incyte Corporation	Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
EP4436669A1 (en)	2021-11-22	2024-10-02	Janssen Biotech, Inc.	Compositions comprising enhanced multispecific binding agents for an immune response
CN118284809A (zh)	2021-11-25	2024-07-02	豪夫迈·罗氏有限公司	少量抗体副产物的定量
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
EP4477669A1 (en)	2022-02-07	2024-12-18	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof
KR20240145492A (ko)	2022-02-11	2024-10-07	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	면역접합체 및 이의 용도
CN120058955A (zh)	2022-03-07	2025-05-30	美勒斯公司	用结合EGFR和cMET的抗体治疗
WO2023172133A1 (en)	2022-03-07	2023-09-14	Merus N.V.	Combination therapy including antibodies that bind egfr and cmet
KR20240161961A (ko)	2022-03-14	2024-11-13	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	Gprc5d 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이의 의약적 용도
WO2023174521A1 (en)	2022-03-15	2023-09-21	Genmab A/S	Binding agents binding to epcam and cd137
JP2025512785A (ja)	2022-03-23	2025-04-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｃｄ２０／抗ｃｄ３二重特異性抗体及び化学療法の併用処置
AU2023251832A1 (en)	2022-04-13	2024-10-17	F. Hoffmann-La Roche Ag	Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
EP4511388A1 (en)	2022-04-19	2025-02-26	F. Hoffmann-La Roche AG	Improved production cells
JP2025516633A (ja)	2022-05-12	2025-05-30	ジェンマブエー／エス	併用療法においてｃｄ２７に結合する能力を有する結合剤
AU2023269545A1 (en)	2022-05-12	2024-11-14	BioNTech SE	Binding agents capable of binding to cd27 in combination therapy
EP4285926A1 (en)	2022-05-30	2023-12-06	LAVA Therapeutics N.V.	Combination treatment for chronic lymphocytic leukemia
JP2025517572A (ja)	2022-06-03	2025-06-05	エフ．ホフマン－ラロシュアーゲー	改良された産生細胞
EP4292610A1 (en)	2022-06-15	2023-12-20	LAVA Therapeutics N.V.	Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en)	2022-06-15	2023-12-20	LAVA Therapeutics N.V.	Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4545564A1 (en)	2022-06-23	2025-04-30	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereof
NL2032398B1 (en)	2022-07-06	2024-01-23	Academisch Ziekenhuis Leiden	Bispecific antibody and uses thereof
WO2024027815A1 (zh)	2022-08-05	2024-02-08	江苏恒瑞医药股份有限公司	特异性结合gucy2c和cd3的抗原结合分子及其医药用途
EP4565619A1 (en)	2022-08-05	2025-06-11	Merus N.V.	Means and methods for treating castration-resistant prostate cancer
TW202423970A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｃｄ３８抗體之組合療法
TW202430211A (zh)	2022-10-10	2024-08-01	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及ｉｍｉｄ之組合療法
TW202423969A (zh)	2022-10-10	2024-06-16	瑞士商赫孚孟拉羅股份公司	Ｇｐｒｃ５ｄｔｃｂ及蛋白酶體抑制劑之組合療法
WO2024079069A1 (en)	2022-10-12	2024-04-18	F. Hoffmann-La Roche Ag	Method for classifying cells
WO2024094660A1 (en)	2022-10-31	2024-05-10	Genmab A/S	Cd38 antibodies and uses thereof
KR20250096769A (ko)	2022-11-01	2025-06-27	상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드	글리피칸-3에 대한 이중특이성 항체 및 이의 용도
AU2023375177A1 (en)	2022-11-02	2025-06-19	Janssen Biotech, Inc.	Methods of treating cancers
WO2024100170A1 (en)	2022-11-11	2024-05-16	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a*02/foxp3
WO2024104988A1 (en)	2022-11-15	2024-05-23	F. Hoffmann-La Roche Ag	Recombinant binding proteins with activatable effector domain
CN120187748A (zh)	2022-11-15	2025-06-20	豪夫迈·罗氏有限公司	抗原结合分子
US20240218070A1 (en)	2022-12-20	2024-07-04	Merus N.V.	FAP BINDING DOMAINS AND BISPECIFIC BINDING MOIETIES THAT BIND FAP AND TGF-ßRII
AU2023408531A1 (en)	2022-12-23	2025-07-17	Merus N.V.	Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
WO2024143442A1 (ja) *	2022-12-27	2024-07-04	中外製薬株式会社	会合が制御されたポリペプチド
WO2024144401A1 (en)	2022-12-28	2024-07-04	Merus N.V.	Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
WO2024153722A1 (en)	2023-01-20	2024-07-25	F. Hoffmann-La Roche Ag	Immunoconjugates
WO2024156672A1 (en)	2023-01-25	2024-08-02	F. Hoffmann-La Roche Ag	Antibodies binding to csf1r and cd3
WO2024163494A1 (en)	2023-01-31	2024-08-08	F. Hoffmann-La Roche Ag	Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
WO2024163009A1 (en)	2023-01-31	2024-08-08	Genentech, Inc.	Methods and compositions for treating urothelial bladder cancer
WO2024184287A1 (en)	2023-03-06	2024-09-12	F. Hoffmann-La Roche Ag	Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024188965A1 (en)	2023-03-13	2024-09-19	F. Hoffmann-La Roche Ag	Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024200573A1 (en)	2023-03-27	2024-10-03	LAVA Therapeutics N.V.	Nectin-4 binding agents and methods of use
EP4438624A1 (en)	2023-03-27	2024-10-02	LAVA Therapeutics N.V.	Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2024208776A1 (en)	2023-04-03	2024-10-10	F. Hoffmann-La Roche Ag	Agonistic split antibodies
WO2024208777A1 (en)	2023-04-03	2024-10-10	F. Hoffmann-La Roche Ag	All-in-one agonistic antibodies
WO2024208898A1 (en)	2023-04-05	2024-10-10	Genmab A/S	Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
WO2024231320A1 (en)	2023-05-08	2024-11-14	F. Hoffmann-La Roche Ag	Targeted interferon alpha fusion proteins and methods of use
TW202509071A (zh)	2023-05-12	2025-03-01	丹麥商珍美寶股份有限公司	能夠與ｏｘ４０結合之抗體、其變異體及其用途
TW202509065A (zh)	2023-05-16	2025-03-01	瑞士商赫孚孟拉羅股份公司	經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
WO2024263904A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2024263195A1 (en)	2023-06-23	2024-12-26	Genentech, Inc.	Methods for treatment of liver cancer
WO2025007037A1 (en)	2023-06-28	2025-01-02	Dragonfly Therapeutics, Inc.	Variant il-2 proteins
US12351650B2 (en)	2023-06-30	2025-07-08	Genmab A/S	Antibodies binding to fibroblast activation protein alpha and death receptor 4
WO2025012118A2 (en)	2023-07-07	2025-01-16	LAVA Therapeutics N.V.	5t4 binding agents and methods of use
WO2025021838A1 (en)	2023-07-26	2025-01-30	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
WO2025024780A1 (en)	2023-07-27	2025-01-30	LAVA Therapeutics N.V.	Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025027511A1 (en)	2023-07-30	2025-02-06	Janssen Biotech, Inc.	Molecules that bind to mutant calreticulin and uses thereof
WO2025034715A1 (en)	2023-08-07	2025-02-13	Janssen Biotech, Inc.	Gucy2c antibodies and uses thereof
WO2025032071A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025036892A1 (en)	2023-08-14	2025-02-20	Morphosys Ag	Cycat halfbody molecules comprising sterically occluding moieties
WO2025042742A1 (en)	2023-08-18	2025-02-27	Bristol-Myers Squibb Company	Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025059162A1 (en)	2023-09-11	2025-03-20	Dana-Farber Cancer Institute, Inc.	Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025056180A1 (en)	2023-09-15	2025-03-20	BioNTech SE	Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025082777A1 (en)	2023-10-17	2025-04-24	Morphosys Ag	Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025105961A1 (en)	2023-11-17	2025-05-22	Merus N.V.	COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.
WO2025114541A1 (en)	2023-11-30	2025-06-05	Genmab A/S	Antibodies capable of binding to ox40 in combination therapy
WO2025125386A1 (en)	2023-12-14	2025-06-19	F. Hoffmann-La Roche Ag	Antibodies that bind to folr1 and methods of use
WO2025137454A1 (en) *	2023-12-21	2025-06-26	Amgen Inc.	Stabilizing homodimer mutations for two cell heterodimer production

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4599311A (en)	1982-08-13	1986-07-08	Kawasaki Glenn H	Glycolytic promotersfor regulated protein expression: protease inhibitor
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
AU600885B2 (en)	1984-05-25	1990-08-30	Zymogenetics Inc.	Stable DNA constructs
DE3583667D1 (de)	1984-12-28	1991-09-05	Atochem	Druckfarbe mit einem strahlenhaertbaren makromer.
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4868103A (en)	1986-02-19	1989-09-19	Enzo Biochem, Inc.	Analyte detection by means of energy transfer
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
US4801687A (en)	1986-10-27	1989-01-31	Bioprobe International, Inc.	Monoclonal antibody purification process using protein A
EP0307667B1 (en)	1987-08-24	1994-04-20	Wacom Company, Ltd.	Coordinate input system with input pen
US4937190A (en)	1987-10-15	1990-06-26	Wisconsin Alumni Research Foundation	Translation enhancer
NZ226694A (en)	1987-10-28	1994-04-27	Oncogen	Human immunoglobulin produced by recombinant dna techniques
ES2035317T5 (es)	1987-11-09	1998-03-16	Becton Dickinson Co	Metodo para analizar celulas hematopoyeticas en una muestra.
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
DE768377T1 (de)	1988-09-02	1998-01-02	Dyax Corp	Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
GB8909218D0 (en)	1989-04-22	1989-06-07	Medical Res Council	Improvements in or relating to enhancers
ATE99958T1 (de)	1989-06-08	1994-01-15	Wistar Inst	Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
WO1991000906A1 (en)	1989-07-12	1991-01-24	Genetics Institute, Inc.	Chimeric and transgenic animals capable of producing human antibodies
US5030002A (en)	1989-08-11	1991-07-09	Becton, Dickinson And Company	Method and apparatus for sorting particles with a moving catcher tube
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5151504A (en)	1989-11-17	1992-09-29	E. R. Squibb & Sons, Inc.	Method for purification of monoclonal antibodies
ES2090299T3 (es)	1989-12-01	1996-10-16	Pharming Bv	Produccion de polipeptidos recombinantes mediante especies bovinas y metodos transgenicos.
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
DE4006630A1 (de)	1990-03-03	1991-09-12	Behringwerke Ag	Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ATE185601T1 (de)	1990-07-10	1999-10-15	Cambridge Antibody Tech	Verfahren zur herstellung von spezifischen bindungspaargliedern
JPH0568599A (ja)	1990-07-31	1993-03-23	Wistar Inst	遺伝子工学的に作られた抗体
IE76732B1 (en)	1990-08-07	1997-11-05	Becton Dickinson Co	One step test for absolute counts
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en)	1995-10-10	2006-05-09	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Antibody production
CA2405246A1 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with alterred binding properties
AU1545692A (en)	1991-03-01	1992-10-06	Protein Engineering Corporation	Process for the development of binding mini-proteins
ES2153358T3 (es)	1991-03-29	2001-03-01	Genentech Inc	Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada.
DE69233750D1 (de)	1991-04-10	2009-01-02	Scripps Research Inst	Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
KR100255717B1 (ko)	1991-07-15	2000-05-01	그레이엄 브레레톤	항체의 생산방법
DE69326967T2 (de)	1992-01-17	2000-06-15	Lakowicz, Joseph R.	Phasenmodulationsenergieübertragungsfluoroimmunassay
US7067284B1 (en)	1992-01-27	2006-06-27	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5667988A (en)	1992-01-27	1997-09-16	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
SE9201984D0 (sv)	1992-06-29	1992-06-29	Pharmacia Biosensor Ab	Improvement in optical assays
WO1994002610A1 (en)	1992-07-17	1994-02-03	Dana-Farber Cancer Institute	Method of intracellular binding of target molecules
ATE381614T1 (de)	1992-07-24	2008-01-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
BR9207175A (pt)	1992-10-28	1995-12-12	Genentech Inc	Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
PT669986E (pt)	1992-11-13	2003-08-29	Idec Pharma Corp	Sequencia do marcador de seleccao dominante alterada e estrategias de insercao intronica para melhoria de expressao de produto genico e sistemas de vector de expressao que o compreendem
AU6498294A (en)	1993-04-07	1994-10-24	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Dna sequence which acts as a chromatin insulator element to protect expressed genes from (cis)-acting regulatory sequences in mammalian cells
DK0698097T3 (da)	1993-04-29	2001-10-08	Unilever Nv	Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US5693506A (en)	1993-11-16	1997-12-02	The Regents Of The University Of California	Process for protein production in plants
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
WO1995017500A1 (en)	1993-12-23	1995-06-29	Abs Global, Inc.	Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
ATE243745T1 (de)	1994-01-31	2003-07-15	Univ Boston	Bibliotheken aus polyklonalen antikörpern
FR2717187B1 (fr)	1994-03-10	1996-05-31	Transgene Sa	Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt.
US6080560A (en)	1994-07-25	2000-06-27	Monsanto Company	Method for producing antibodies in plant cells
JPH08116978A (ja)	1994-10-18	1996-05-14	Nisshinbo Ind Inc	抗体Ｆａｂライブラリーの作製法
AU722668B2 (en)	1994-12-30	2000-08-10	King's College London	Methods for producing immunoglobulins containing protection proteins in plants and their use
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
US5783186A (en)	1995-12-05	1998-07-21	Amgen Inc.	Antibody-induced apoptosis
US5885827A (en)	1996-01-23	1999-03-23	The Regents Of The Universtiy Of California	Eukaryotic high rate mutagenesis system
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6825396B2 (en)	1996-06-12	2004-11-30	Board Of Trustees Operating Michigan State University	Methods for tissue specific synthesis of protein in eggs of transgenic hens
ES2190543T3 (es)	1996-10-08	2003-08-01	Bisys B V U	Procedimientos y sistemas que permiten seleccionar peptidos y proteinas que tienen una afinidad especifica respecto a un blanco.
GB9621113D0 (en)	1996-10-10	1996-11-27	Univ Southampton	Transgenic fish
JP2001505055A (ja)	1996-12-02	2001-04-17	ウエイク・フオレスト・ユニバーシテイ	Ｈｉｖ感染の治療としてのｈｉｖコレセプターの不活性化
AU738328B2 (en)	1997-01-21	2001-09-13	General Hospital Corporation, The	Selection of proteins using RNA-protein fusions
BR9808192A (pt)	1997-03-06	2000-10-24	Infigen Inc	Processo de clonagem de animais
CZ293355B6 (cs)	1997-03-14	2004-04-14	Idec Pharmaceuticals Corporation	Způsob integrace genů do specifických míst genomu savčí buňky homologní rekombinací a příslušné vektorové systémy
US6080912A (en)	1997-03-20	2000-06-27	Wisconsin Alumni Research Foundation	Methods for creating transgenic animals
DE69836729T2 (de)	1997-04-07	2007-12-13	Genentech, Inc., South San Francisco	Anti-vefg antibodies
ES2246069T3 (es)	1997-05-02	2006-02-01	Genentech, Inc.	Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en)	1997-05-02	2003-11-06	William R. Arathoon	Method for making multispecific antibodies having heteromultimeric and common components
EP0983303B1 (en)	1997-05-21	2006-03-08	Biovation Limited	Method for the production of non-immunogenic proteins
WO1999015684A2 (en)	1997-09-23	1999-04-01	Oxford Biomedica (Uk) Limited	Expression of genes in hematopoietic stem cells in hischaemic conditions
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
CN1203178C (zh)	1997-10-27	2005-05-25	尤尼利弗公司	多价抗原结合蛋白
DE69823652D1 (de)	1997-11-26	2004-06-09	Mitsubishi Precision Co Ltd	Informationsleitungssystem
WO1999050657A1 (en)	1998-03-30	1999-10-07	Research Development Foundation	Corticotropin releasing factor receptor 1-deficient mice
US6413776B1 (en)	1998-06-12	2002-07-02	Galapagos Geonomics N.V.	High throughput screening of gene function using adenoviral libraries for functional genomics applications
GB9823930D0 (en)	1998-11-03	1998-12-30	Babraham Inst	Murine expression of human ig\ locus
IL144578A0 (en)	1999-01-29	2002-05-23	Imclone Systems Inc	Antibodies specific to kdr and uses thereof
DK1161548T4 (da)	1999-04-15	2010-03-01	Crucell Holland Bv	Rekombinant proteinproduktion i en human celle under anvendelse af sekvenser, der koder for adenovirus E1-protein
EP2067788B1 (en)	1999-05-18	2015-07-22	Dyax Corp.	Fab fragment libraries and methods for their use
US6472147B1 (en)	1999-05-25	2002-10-29	The Scripps Research Institute	Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6833268B1 (en)	1999-06-10	2004-12-21	Abgenix, Inc.	Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001000245A2 (en)	1999-06-25	2001-01-04	Genentech, Inc.	HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2001019394A2 (en)	1999-09-15	2001-03-22	Therapeutic Human Polyclonals, Inc.	Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
US6180357B1 (en)	1999-10-08	2001-01-30	Arius Research, Inc.	Individualized patient-specific anti-cancer antibodies
AU7676300A (en)	1999-10-12	2001-04-23	Cambridge Antibody Technology Limited	Human anti-adipocyte monoclonal antibodies and their use
WO2001032901A1 (en)	1999-11-01	2001-05-10	Chiron Corporation	Expression vectors, transfection systems, and method of use thereof
GB9928787D0 (en)	1999-12-03	2000-02-02	Medical Res Council	Direct screening method
NZ520074A (en)	1999-12-27	2004-04-30	Crucell Holland B	Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope
EP1268832A4 (en)	2000-02-29	2003-04-02	Univ Auburn	PRODUCTION OF ANTIBODIES IN TRANSGENIC PLASTIDES
US20040180046A1 (en)	2000-04-26	2004-09-16	Jeff Himawan	Bispecific molecules and uses thereof
ATE321069T1 (de)	2000-05-12	2006-04-15	Vlaams Interuniv Inst Biotech	Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
DE60136174D1 (de)	2000-05-16	2008-11-27	Univ Jefferson	Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren
MXPA02012867A (es)	2000-06-29	2003-09-05	Abbott Lab	Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
EP1184458A1 (en)	2000-08-28	2002-03-06	U-BISys B.V.	Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
EP1188771A1 (en)	2000-09-15	2002-03-20	U-BISys B.V.	Libraries of human heavy chain variable fragments in a functional format
US7737258B2 (en)	2000-10-18	2010-06-15	Sloan-Kettering Institute For Cancer Research	Uses of monoclonal antibody 8H9
US7105348B2 (en)	2000-10-31	2006-09-12	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CN1487996B (zh)	2000-11-30	2010-06-16	米德列斯公司	用于生产人类抗体的转基因转染色体啮齿动物
FR2817875B1 (fr)	2000-12-07	2005-03-18	Technopharm	Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation
DK1356037T3 (da)	2001-01-25	2011-06-27	Evolva Ltd	Bibliotek med en samling af celler
JP4307079B2 (ja)	2001-01-26	2009-08-05	セレキスエスアー	マトリックス付着領域およびその使用方法
AU2002327164A1 (en)	2001-01-29	2002-12-09	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
MXPA03008454A (es)	2001-03-22	2004-06-30	Abbott Gmbh & Co Kg	Animales transgenicos que expresan anticuerpos especificos para genes de interes y usos de los mismos.
GB0110029D0 (en)	2001-04-24	2001-06-13	Grosveld Frank	Transgenic animal
US7595378B2 (en)	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
IL159225A0 (en)	2001-06-13	2004-06-01	Genmab As	Human monoclonal antibodies to epidermal growth factor receptor (egfr)
ES2257560T3 (es)	2001-06-15	2006-08-01	Crucell Holland B.V.	Fagos quimericos.
WO2004003211A1 (en)	2002-06-26	2004-01-08	Imclone Systems Incorporated	Bispecific antibodies that bind to vegf receptors
EP1399484B1 (en)	2001-06-28	2010-08-11	Domantis Limited	Dual-specific ligand and its use
ATE466941T1 (de)	2001-07-04	2010-05-15	Chromagenics Bv	Dns-sequenzen mit anti-repressor-aktivität
NZ531291A (en)	2001-08-21	2006-02-24	Univ Jefferson	Recombinant anti rabies antibodies MAb JB.1 and Mab 57 and compositions and methods for making and using the same
DE60224291T2 (de)	2001-08-27	2008-12-11	Genentech, Inc., South San Francisco	System zur antikörperexpression und- synthese
WO2003048306A2 (en)	2001-11-16	2003-06-12	Idec Pharmaceuticals Corporation	Polycistronic expression of antibodies
BR0214621A (pt)	2001-11-30	2004-10-13	Ca Nat Research Council	Moléculas de automontagem
EP1451226A1 (en)	2001-11-30	2004-09-01	Crucell Holland B.V.	Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
GB0130267D0 (en)	2001-12-19	2002-02-06	Neutec Pharma Plc	Focussed antibody technology
US7244592B2 (en)	2002-03-07	2007-07-17	Dyax Corp.	Ligand screening and discovery
GB2387030A (en)	2002-03-26	2003-10-01	Thales Plc	Compensation of mutual coupling in array antenna systems
WO2003107218A1 (ja)	2002-05-31	2003-12-24	セレスター・レキシコ・サイエンシズ株式会社	相互作用予測装置
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
CA2489475C (en)	2002-06-14	2011-03-29	Chromagenics B.V.	A method for simultaneous production of multiple proteins; vectors and cells for use therein
EP1513936A2 (en)	2002-06-14	2005-03-16	Chromagenics B.V.	Use of repression blocking sequences in methods for enhancing gene expression
US20080241166A1 (en)	2002-06-28	2008-10-02	Domantis Limited	Ligands that bind a receptor
CN1328446C (zh)	2002-07-10	2007-07-25	阿戈什蒂诺·迪特拉帕尼	建筑元件
ES2368733T3 (es)	2002-07-18	2011-11-21	Merus B.V.	Producción recombinante de mezclas de anticuerpos.
JP4589914B2 (ja)	2003-01-07	2010-12-01	シムフォゲン・アクティーゼルスカブ	組換え型ポリクローナルタンパク質の製造方法
EP1439234A1 (en)	2003-01-08	2004-07-21	ARTEMIS Pharmaceuticals GmbH	Targeted transgenesis using the rosa26 locus
EP2395016A3 (en)	2003-05-30	2012-12-19	Merus B.V.	Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
EP2322547A1 (en)	2003-06-25	2011-05-18	Crucell Holland B.V.	Myeloid cell-specific lectin
WO2005012360A2 (en)	2003-07-22	2005-02-10	Crucell Holland B.V.	Binding molecules against sars-coronavirus and uses thereof
ATE536376T1 (de)	2003-12-23	2011-12-15	Crucell Holland Bv	Humanes bindungsmolekül gegen cd1a
AU2005205412B2 (en)	2004-01-20	2011-08-11	Merus N.V.	Mixtures of binding proteins
RS51847B (en)	2004-05-27	2012-02-29	Crucell Holland Bv.	BINDING MOLECULES WHICH MAY NEUTRALIZE FRAGILE VIRUS AND USE
MXPA06014075A (es)	2004-06-03	2007-03-15	Novimmune Sa	Anticuerpos anti-cd3 y metodos de uso de los mismos.
JP2008511337A (ja)	2004-09-02	2008-04-17	ジェネンテック・インコーポレーテッド	ヘテロ多量体分子
JP4852046B2 (ja)	2004-10-12	2012-01-11	クルセルホランドベーヴェー	癌の治療及び検出に用いる結合分子
JP4487068B2 (ja)	2004-10-12	2010-06-23	国立大学法人岡山大学	細胞の遺伝子変異機能の制御による変異タンパク質の作製方法
SG159542A1 (en)	2004-11-11	2010-03-30	Crucell Holland Bv	Compositions against sars-coronavirus and uses thereof
ES2592271T3 (es)	2005-03-31	2016-11-29	Chugai Seiyaku Kabushiki Kaisha	Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
WO2006117699A2 (en)	2005-04-29	2006-11-09	Innate Pharma	Transgenic animals and methods of making recombinant antibodies
ATE507242T1 (de)	2005-05-12	2011-05-15	Crucell Holland Bv	Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
US20090130652A1 (en)	2005-06-23	2009-05-21	Crucell Holland B.V.	Optimization of West Nile Virus Antibodies
EP1928914A2 (en)	2005-09-15	2008-06-11	Crucell Holland B.V.	Method for preparing immunoglobulin libraries
ZA200804337B (en) *	2005-11-28	2009-11-25	Genmab As	Recombinant monovalent antibodies and methods for production thereof
JP5525729B2 (ja)	2005-11-28	2014-06-18	ゲンマブエー／エス	組換え一価抗体およびその作製方法
WO2007110205A2 (en)	2006-03-24	2007-10-04	Merck Patent Gmbh	Engineered heterodimeric protein domains
EP2003960B1 (en)	2006-03-31	2015-06-10	E. R. Squibb & Sons, L.L.C.	Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2377579T3 (es)	2006-06-02	2012-03-29	Regeneron Pharmaceuticals, Inc.	Anticuerpos de alta afinidad contra el receptor de IL-6 humano
KR101508390B1 (ko)	2006-06-06	2015-04-08	크루셀 홀란드 비.브이.	포도상구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
AU2007255388B2 (en)	2006-06-06	2013-07-04	Crucell Holland B.V.	Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
EP2035456A1 (en)	2006-06-22	2009-03-18	Novo Nordisk A/S	Production of bispecific antibodies
US10118970B2 (en)	2006-08-30	2018-11-06	Genentech, Inc.	Multispecific antibodies
KR101485197B1 (ko)	2006-09-07	2015-01-23	크루셀 홀란드 비.브이.	인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도
MEP11109A (en)	2006-10-02	2011-12-20		High affinity human antibodies to human il-4 receptor
US8290739B2 (en)	2006-10-20	2012-10-16	Amfit, Inc.	Method for determining relative mobility of regions of an object
NO347649B1 (no)	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CA2681974C (en)	2007-03-29	2019-12-31	Genmab A/S	Bispecific antibodies and methods for production thereof
ITMI20071522A1 (it)	2007-07-27	2009-01-28	Areta Internat S R L	Vaccino idiotipico
AU2008287340A1 (en)	2007-08-15	2009-02-19	Amunix, Inc.	Compositions and methods for modifying properties of biologically active polypeptides
DK3124497T3 (da)	2007-09-14	2020-05-11	Adimab Llc	Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf
EP2211903A4 (en)	2007-10-17	2011-07-06	Nuvelo Inc	CLL-1 ANTIBODY
US8242247B2 (en)	2007-12-21	2012-08-14	Hoffmann-La Roche Inc.	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
AU2009204501B2 (en) *	2008-01-07	2015-02-12	Amgen Inc.	Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US9404928B2 (en)	2008-02-05	2016-08-02	Zymeworks Inc.	Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics
SI2147594T1 (sl)	2008-06-27	2014-02-28	Merus B.V.	Protitelo proizvajajoči ne-humani sesalci
WO2010084197A1 (en) *	2009-01-26	2010-07-29	Genmab A/S	Methods for producing mixtures of antibodies
TWI461211B (zh)	2009-03-20	2014-11-21	Genentech Inc	抗－ｈｅｒ抗體
AU2010245011B2 (en)	2009-04-27	2015-09-03	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
CN105418757B (zh)	2009-05-11	2019-07-09	扬森疫苗与预防公司	能中和流感病毒h3n2的人结合分子及其应用
MX342623B (es)	2009-06-26	2016-10-06	Regeneron Pharma	Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
US8765900B2 (en)	2009-08-27	2014-07-01	Bayer Materialscience Llc	Aliphatic moisture-curable resins, coating compositions, and related processes
US9493578B2 (en) *	2009-09-02	2016-11-15	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781539C (en)	2009-11-23	2021-07-20	Amgen Inc.	Monomeric antibody fc
US20120021409A1 (en)	2010-02-08	2012-01-26	Regeneron Pharmaceuticals, Inc.	Common Light Chain Mouse
RU2724663C2 (ru)	2010-02-08	2020-06-25	Ридженерон Фармасьютикалз, Инк.	Мышь с общей легкой цепью
US9527926B2 (en) *	2010-05-14	2016-12-27	Rinat Neuroscience Corp.	Heterodimeric proteins and methods for producing and purifying them
WO2012020096A1 (en) *	2010-08-13	2012-02-16	Medimmune Limited	Monomeric polypeptides comprising variant fc regions and methods of use
CA2808482C (en)	2010-08-16	2021-10-26	Novimmune S.A.	Methods for the generation of multispecific and multivalent antibodies
JP6167040B2 (ja) *	2010-11-05	2017-07-19	ザイムワークス，インコーポレイテッド	Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
DK4067496T5 (da)	2011-02-25	2024-07-22	Regeneron Pharma	ADAM6-mus
KR20200052383A (ko)	2011-03-25	2020-05-14	아이크노스 사이언스 에스. 아.	헤테로 이량체 면역글로불린
JP2013004215A (ja)	2011-06-14	2013-01-07	Hitachi Ltd	リチウムイオン二次電池
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
MX353278B (es)	2012-03-06	2018-01-05	Regeneron Pharma	Raton con cadena ligera comun.
PL2838917T3 (pl) *	2012-04-20	2019-12-31	Merus N.V.	Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do Ig
WO2013184761A1 (en)	2012-06-05	2013-12-12	Regeneron Pharmaceuticals, Inc.	Methods for making fully human bispecific antibodies using a common light chain
ES2692951T3 (es)	2012-09-27	2018-12-05	Merus N.V.	Anticuerpos IgG biespecíficos como acopladores de células T
UY35148A (es) *	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
US10798961B2 (en)	2013-03-15	2020-10-13	Altria Client Services Llc	Functional food and beverage compositions with improved taste through the use of sensates
JP7010811B2 (ja)	2015-07-10	2022-02-10	メルスナムローゼフェンノートシャップ	ヒトｃｄ３結合抗体

2013
- 2013-04-19 PL PL13720614T patent/PL2838917T3/pl unknown
- 2013-04-19 KR KR1020257003984A patent/KR20250025034A/ko active Pending
- 2013-04-19 HR HRP20191409 patent/HRP20191409T1/hr unknown
- 2013-04-19 US US13/866,756 patent/US9248182B2/en active Active
- 2013-04-19 CA CA2870821A patent/CA2870821C/en active Active
- 2013-04-19 SM SM20190493T patent/SMT201900493T1/it unknown
- 2013-04-19 NZ NZ772318A patent/NZ772318A/en unknown
- 2013-04-19 ES ES13720614T patent/ES2743399T3/es active Active
- 2013-04-19 US US14/395,330 patent/US20150139996A1/en not_active Abandoned
- 2013-04-19 SG SG10201607369QA patent/SG10201607369QA/en unknown
- 2013-04-19 CN CN201810296908.XA patent/CN108586610A/zh active Pending
- 2013-04-19 SG SG10201913376XA patent/SG10201913376XA/en unknown
- 2013-04-19 SG SG11201406770WA patent/SG11201406770WA/en unknown
- 2013-04-19 NZ NZ802035A patent/NZ802035A/en unknown
- 2013-04-19 SG SG10201913634VA patent/SG10201913634VA/en unknown
- 2013-04-19 CA CA2871068A patent/CA2871068C/en active Active
- 2013-04-19 EP EP13720614.0A patent/EP2838917B1/en active Active
- 2013-04-19 NZ NZ630568A patent/NZ630568A/en unknown
- 2013-04-19 EP EP19178196.2A patent/EP3594233A1/en active Pending
- 2013-04-19 SG SG10201607371UA patent/SG10201607371UA/en unknown
- 2013-04-19 WO PCT/NL2013/050293 patent/WO2013157953A1/en active IP Right Grant
- 2013-04-19 LT LTEP13720615.7T patent/LT2838918T/lt unknown
- 2013-04-19 KR KR1020147032231A patent/KR102104601B1/ko active Active
- 2013-04-19 AU AU2013249986A patent/AU2013249986B2/en active Active
- 2013-04-19 KR KR1020207001067A patent/KR102269650B1/ko active Active
- 2013-04-19 RS RSP20191034 patent/RS59263B1/sr unknown
- 2013-04-19 JP JP2015506928A patent/JP6393255B2/ja active Active
- 2013-04-19 EA EA202090591A patent/EA202090591A3/ru unknown
- 2013-04-19 PT PT13720615T patent/PT2838918T/pt unknown
- 2013-04-19 RS RSP20190999 patent/RS59260B1/sr unknown
- 2013-04-19 DK DK13720615.7T patent/DK2838918T3/da active
- 2013-04-19 CN CN202111365429.7A patent/CN114163530B/zh active Active
- 2013-04-19 KR KR1020237019940A patent/KR20230093359A/ko not_active Ceased
- 2013-04-19 CN CN201710637343.2A patent/CN107383197B/zh active Active
- 2013-04-19 AU AU2013249985A patent/AU2013249985B2/en active Active
- 2013-04-19 NZ NZ799532A patent/NZ799532A/en unknown
- 2013-04-19 LT LTEP13720614.0T patent/LT2838917T/lt unknown
- 2013-04-19 US US14/395,325 patent/US20150196637A1/en not_active Abandoned
- 2013-04-19 HU HUE13720615A patent/HUE045945T2/hu unknown
- 2013-04-19 EA EA201491908A patent/EA201491908A1/ru unknown
- 2013-04-19 DK DK13720614.0T patent/DK2838917T3/da active
- 2013-04-19 PT PT13720614T patent/PT2838917T/pt unknown
- 2013-04-19 SI SI201331534T patent/SI2838918T1/sl unknown
- 2013-04-19 EA EA201491909A patent/EA035344B1/ru not_active IP Right Cessation
- 2013-04-19 NZ NZ630551A patent/NZ630551A/en unknown
- 2013-04-19 HR HRP20191446 patent/HRP20191446T1/hr unknown
- 2013-04-19 JP JP2015506927A patent/JP6272299B2/ja active Active
- 2013-04-19 CN CN201380032190.9A patent/CN104520319B/zh active Active
- 2013-04-19 KR KR1020227011508A patent/KR102545770B1/ko active Active
- 2013-04-19 KR KR1020237019942A patent/KR20230091201A/ko not_active Ceased
- 2013-04-19 SI SI201331553T patent/SI2838917T1/sl unknown
- 2013-04-19 HU HUE13720614A patent/HUE045944T2/hu unknown
- 2013-04-19 ES ES13720615T patent/ES2740749T3/es active Active
- 2013-04-19 MX MX2014012700A patent/MX360109B/es active IP Right Grant
- 2013-04-19 CN CN201380032276.1A patent/CN104520320B/zh active Active
- 2013-04-19 SM SM20190488T patent/SMT201900488T1/it unknown
- 2013-04-19 EP EP13720615.7A patent/EP2838918B1/en active Active
- 2013-04-19 EP EP19177410.8A patent/EP3594232A1/en active Pending
- 2013-04-19 US US13/866,747 patent/US9248181B2/en active Active
- 2013-04-19 WO PCT/NL2013/050294 patent/WO2013157954A1/en not_active Application Discontinuation
- 2013-04-19 KR KR1020207030488A patent/KR20200126007A/ko not_active Ceased
- 2013-04-19 KR KR1020147032229A patent/KR102171431B1/ko active Active
- 2013-04-19 MX MX2014012701A patent/MX360110B/es active IP Right Grant
- 2013-04-19 SG SG11201406772YA patent/SG11201406772YA/en unknown
- 2013-04-19 KR KR1020207011173A patent/KR102382304B1/ko active Active
- 2013-04-19 PL PL13720615T patent/PL2838918T3/pl unknown
- 2013-11-15 US US14/081,848 patent/US9358286B2/en active Active
2014
- 2014-10-20 MX MX2018012766A patent/MX2018012766A/es unknown
- 2014-10-20 MX MX2024012548A patent/MX2024012548A/es unknown
- 2014-10-20 MX MX2024012547A patent/MX2024012547A/es unknown
- 2014-10-20 MX MX2018012769A patent/MX2018012769A/es unknown
- 2014-10-27 ZA ZA2014/07834A patent/ZA201407834B/en unknown
- 2014-10-27 ZA ZA2014/07835A patent/ZA201407835B/en unknown
2015
- 2015-12-18 US US14/974,581 patent/US9758805B2/en active Active
2016
- 2016-05-16 US US15/155,743 patent/US10329596B2/en active Active
2017
- 2017-04-25 US US15/496,807 patent/US10337045B2/en active Active
- 2017-12-28 JP JP2017254422A patent/JP6639464B2/ja active Active
2018
- 2018-02-23 AU AU2018201326A patent/AU2018201326B2/en active Active
- 2018-02-23 AU AU2018201325A patent/AU2018201325B2/en active Active
- 2018-08-24 JP JP2018157537A patent/JP6781740B2/ja active Active
2019
- 2019-05-20 US US16/417,379 patent/US10752929B2/en active Active
- 2019-08-05 CY CY20191100831T patent/CY1122153T1/el unknown
- 2019-08-28 CY CY20191100914T patent/CY1122118T1/el unknown
- 2019-12-24 JP JP2019233206A patent/JP2020089366A/ja active Pending
2020
- 2020-07-21 US US16/934,925 patent/US12123043B2/en active Active
- 2020-08-20 JP JP2020139295A patent/JP2020202854A/ja active Pending
2023
- 2023-02-28 JP JP2023030194A patent/JP2023060019A/ja active Pending
- 2023-05-16 US US18/318,507 patent/US11926859B2/en active Active
2024
- 2024-02-02 US US18/431,564 patent/US20240344102A1/en active Pending
- 2024-10-07 JP JP2024175774A patent/JP2024180421A/ja active Pending

Also Published As

Publication number	Publication date
MX2018012766A (es)	2021-11-16
MX2024012547A (es)	2024-12-06
HUE045945T2 (hu)	2020-02-28
ZA201407834B (en)	2015-12-23
JP2020089366A (ja)	2020-06-11
SG10201913376XA (en)	2020-02-27
CN104520320B (zh)	2018-05-01
AU2018201326A1 (en)	2018-03-15
AU2013249986A1 (en)	2014-11-06
MX360110B (es)	2018-10-23
US9358286B2 (en)	2016-06-07
KR20230091201A (ko)	2023-06-22
JP6639464B2 (ja)	2020-02-05
US11926859B2 (en)	2024-03-12
HK1206041A1 (en)	2015-12-31
JP2024180421A (ja)	2024-12-26
JP6272299B2 (ja)	2018-01-31
EP3594233A1 (en)	2020-01-15
US9248181B2 (en)	2016-02-02
PL2838917T3 (pl)	2019-12-31
NZ630568A (en)	2017-06-30
LT2838918T (lt)	2019-09-10
US20210071222A1 (en)	2021-03-11
SG10201607369QA (en)	2016-10-28
JP6393255B2 (ja)	2018-09-19
EA202090591A2 (ru)	2020-08-31
SMT201900493T1 (it)	2019-11-13
RS59260B1 (sr)	2019-10-31
KR20150035534A (ko)	2015-04-06
JP2020202854A (ja)	2020-12-24
KR20220046711A (ko)	2022-04-14
WO2013157953A1 (en)	2013-10-24
KR20200047724A (ko)	2020-05-07
CN108586610A (zh)	2018-09-28
PT2838918T (pt)	2019-08-23
EA201491909A1 (ru)	2015-03-31
US10337045B2 (en)	2019-07-02
CY1122118T1 (el)	2020-11-25
CN107383197A (zh)	2017-11-24
AU2018201326B2 (en)	2020-02-06
ES2743399T3 (es)	2020-02-19
US20200017897A1 (en)	2020-01-16
US20130336981A1 (en)	2013-12-19
EP2838918A1 (en)	2015-02-25
CN114163530A (zh)	2022-03-11
EA035344B1 (ru)	2020-05-29
LT2838917T (lt)	2019-09-25
JP6781740B2 (ja)	2020-11-04
AU2013249985B2 (en)	2017-11-23
CA2870821C (en)	2022-06-14
NZ772318A (en)	2023-06-30
HRP20191446T1 (hr)	2019-11-15
US9248182B2 (en)	2016-02-02
SG11201406772YA (en)	2014-11-27
KR102171431B1 (ko)	2020-10-30
KR20230093359A (ko)	2023-06-27
HRP20191409T1 (hr)	2019-11-15
EP3594232A1 (en)	2020-01-15
KR102545770B1 (ko)	2023-06-21
MX2024012548A (es)	2024-12-06
NZ728228A (en)	2021-02-26
AU2018201325A1 (en)	2018-03-15
US20140140999A1 (en)	2014-05-22
JP2019022489A (ja)	2019-02-14
CN104520319A (zh)	2015-04-15
AU2013249986B2 (en)	2017-11-23
SMT201900488T1 (it)	2019-11-13
EP2838917B1 (en)	2019-06-05
KR20200015756A (ko)	2020-02-12
ZA201407835B (en)	2015-12-23
EP2838917A1 (en)	2015-02-25
SG10201607371UA (en)	2016-10-28
JP2023060019A (ja)	2023-04-27
US10329596B2 (en)	2019-06-25
MX2018012769A (es)	2021-11-16
EA201491908A1 (ru)	2015-03-31
CN104520319B (zh)	2017-08-25
PT2838917T (pt)	2019-09-12
AU2018201325B2 (en)	2020-02-06
CA2871068C (en)	2022-06-14
DK2838917T3 (da)	2019-08-26
SG11201406770WA (en)	2014-11-27
WO2013157954A1 (en)	2013-10-24
CA2870821A1 (en)	2013-10-24
MX2014012701A (es)	2014-12-05
EP2838918B1 (en)	2019-06-05
CY1122153T1 (el)	2020-11-25
US12123043B2 (en)	2024-10-22
DK2838918T3 (da)	2019-08-12
RS59263B1 (sr)	2019-10-31
ES2740749T3 (es)	2020-02-06
NZ799532A (en)	2023-07-28
AU2013249985A1 (en)	2014-11-06
EA202090591A3 (ru)	2020-12-30
SI2838917T1 (sl)	2019-11-29
US20150196637A1 (en)	2015-07-16
US20170327860A1 (en)	2017-11-16
PL2838918T3 (pl)	2019-11-29
NZ802035A (en)	2025-02-28
MX2014012700A (es)	2014-12-05
US20160177364A1 (en)	2016-06-23
SG10201913634VA (en)	2020-03-30
KR102104601B1 (ko)	2020-06-01
US20170369923A1 (en)	2017-12-28
JP2018099119A (ja)	2018-06-28
HK1206039A1 (en)	2015-12-31
KR102382304B1 (ko)	2022-04-04
CN114163530B (zh)	2025-04-29
MX360109B (es)	2018-10-23
US20140072579A1 (en)	2014-03-13
CN104520320A (zh)	2015-04-15
CA2871068A1 (en)	2013-10-24
US20150139996A1 (en)	2015-05-21
JP2015514417A (ja)	2015-05-21
KR20200126007A (ko)	2020-11-05
KR20150035535A (ko)	2015-04-06
US20230340556A1 (en)	2023-10-26
NZ630551A (en)	2017-11-24
KR20250025034A (ko)	2025-02-20
SI2838918T1 (sl)	2019-11-29
US9758805B2 (en)	2017-09-12
KR102269650B1 (ko)	2021-06-28
US20240344102A1 (en)	2024-10-17
US10752929B2 (en)	2020-08-25
JP2015515275A (ja)	2015-05-28
CN107383197B (zh)	2021-12-10

Publication	Publication Date	Title
HUE045944T2 (hu)	2020-02-28	Eljárások és eszközök heterodimerikus IG-szerû molekulák elõállítására
EP2930714A4 (en)	2016-11-09	Singing voice synthesizing system and singing voice synthesizing method
DK2850202T3 (da)	2020-05-18	Fremgangsmåder og grupper
EP2698985A4 (en)	2015-06-24	Imaging system and imaging method
KR101849656B9 (ko)	2024-11-27	디스플레이 장치의 제조방법, 디스플레이 장치의 제조장치
EP2900153A4 (en)	2016-06-15	SYSTEM AND APPARATUS FOR VISUALIZING TROCART OPTICAL
HUE042162T2 (hu)	2019-06-28	Fröccsöntött szitaberendezés és eljárás
DK2867743T3 (da)	2019-05-27	Serverhukommelse-køleapparat
BR112015007125A2 (pt)	2017-07-04	aparelho e método
PT2936476T (pt)	2016-11-30	Aparelho de visualização
EP2818054A4 (en)	2015-10-21	METHOD FOR COOKING STEAM NOODLES AND DEVICE FOR COOKING STEAM NOODLES
EP2874367A4 (en)	2015-10-21	CALL AUTHENTICATION METHOD, DEVICE AND SYSTEM
DE112013003437T8 (de)	2015-04-30	Analysesystem und Analyseverfahren
BR112015002671A2 (pt)	2017-08-01	método e aparelho
HUE036131T2 (hu)	2018-06-28	Berendezés és eljárás panelek elõállítására
BR112016010122A2 (pt)	2017-08-01	processo de síntese de poliamida e poliamida
EP2898155A4 (en)	2016-07-06	DEVICE FOR AN EXECUTIVE STRUCTURE
EP2826150A4 (en)	2015-11-18	turbo
FR2989267B1 (fr)	2015-06-26	Appareil aspire-salive
TH1301006881B (th)	2016-02-05	กรรมวิธีเพื่อการผลิตไฮโดรคาร์บอนเหลว
ITMO20120003U1 (it)	2013-08-22	Slitta costipatrice vibrante per grader e ruspe
TH1301006882B (th)	2016-02-05	กรรมวิธีและเครื่องเพื่อการผลิตไฮโดรคาร์บอนเหลว
TH1401005742A (th)	2016-03-04	หัวเผาและวิธีการสำหรับการผลิตหัวเผา
TH1401005740A (th)	2016-05-04	หัวเผาและวิธีการสำหรับการผลิตหัวเผา
TH1501001137A (th)	2016-07-06	เม็ดกรานูลและวิธีผลิตเม็ดกรานูล